Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 1999

View Archived Issues

UC Irvine and NeoTherapeutics enter research and licensing agreement

Myriad Genetics identifies diabetes gene

Antex Biologics and SB restructure agreement

Novartis receives approvable letter from FDA for Trileptal

Jak2 tyrosine kinase inhibitor prevents cell proliferation in ALL cells in vitro

Positive inotropic activity of EMD-57033 is maintained during MI

Novel natriuretic peptide is a candidate for treating CHF

Conivaptan effectively and safely reverses hyponatremia in patients with CHF

Roche presents antiproliferative retiferol derivatives particularly useful for psoriasis

Calcium channel blockers described in recently issued patent by Warner-Lambert

Protein farnesyltransferase inhibitors developed at Schering-Plough

New compounds for inflammatory conditions from Genetics Institute act by inhibiting PLA2

ECCO 10 presentation for a novel VEGF receptor TK inhibitor

New prescribing information for flutamide

Orally active, non-neurotoxic anticonvulsants and EAA antagonists designed by K & K Biosciences

Results of phase III becaplermin study in pressure ulcers are inconsistent with phase II findings

More brain GABA-A receptor ligands in the Neurogen pipeline

Licensing opportunity from NIH: thiazepine inhibitors of HIV-1 integrase

Further efforts in the area of 2-pyridone antibacterials described by Abbott at ICAAC

IntraDose featured in several ECCO 10 presentations; clinical results consistently positive

Clinical candidate selected by Wakunaga from series of antibacterial 8-methylquinolones

J-110441: a broad-spectrum carbapenem-derived beta-lactamase inhibitor designed at Banyu

Gilead's once-daily anti-HIV agent effective and safe in patients, as reported at ICAAC

Duloxetine safety and pharmacokinetics determined in healthy volunteers

Ondansetron effectively controls tardive dyskinesia and improves symptoms of psychosis

EntreMed's first phase I study of Endostatin now enrolling patients

New Lilly compounds LY-314177 and LY-311912 active against influenza A infections in mice

Identification of tetracycline resistance reverser reported at ICAAC by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...